Aineistot 11-20 / 32
(Turun yliopisto, 2016-11-01)
Kohtukuolemat Tyksissä vuosina 2001-2011
(Turun yliopisto, 2016-09-14)
Histological detection and prognostic value of regulators of metaphase-anaphase transition in breast cancer
(Turun yliopisto, 2018-12-14)
The study focuses on proteins Securin, Pttg1IP and Separase, involved in metaphase-anaphase transition of mitosis, and microRNAs -494, -205, -21 and -126 in association with cell proliferation. The aim is to demonstrate ...
Virtuaaliset ja digitaaliset materiaalit patologian opetuksessa Suomessa
(Turun yliopisto, 2018-03-07)
Regulation of MYC activity by post-translational modifications
MYC is a transcription factor that is often found deregulated in cancer. Post-translational modifications, including phosphorylation and ubiquitination, play important role in controlling MYC expression and activity. This ...
A Systems Biology Analysis of PP2A Functions in Cancer Cells
(Annales Universitatis Turkuensis D 1264Turun yliopisto, 2017-01-20)
Cancer is characterized by aberrant activation of phosphorylation signalling cascades. However, despite the critical role of phosphatases in protein phosphorylation, their contribution to cancer cell signalling is only ...
The Role of PME-1 in Cancer: Therapeutic Implication
(Annales Universitatis Turkuensis D 1238Turun yliopisto, 2016-08-19)
Protein phosphatase 2A (PP2A) plays a major role in maintaining cellular signaling homeostasis in human cells by reversibly affecting the phosphorylation of a variety of proteins. Protein phosphatase ...
Biomarkers in stage II colorectal cancer
(Turun yliopisto, 2020-02-21)
The risk of recurrence of stage II colorectal cancer is difficult to predict. A part of recurrences take place among patients without any of the known high-risk factors such as lymphovascular invasion or preoperative ...
Securin-related cell proliferation in breast cancer prognosis
(Turun yliopisto, 2020-03-13)
Breast cancer is the most common malignancy among women. It remains a major cause of mortality among women, although the five-year survival of breast cancer patients is about 90%. To aid in the clinical treatment decisions, ...